Dosage & Administration
Cutaquig is for subcutaneous use only
Do not inject into a blood vessel.
- Before switching to cutaquig, obtain patient’s serum immunoglobulin G (IgG) trough level to guide subsequent dose adjustments. Individualize dose based on patient’s pharmacokinetic and clinical response. Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Switching from IVIg to cutaquig:
Calculate dosing by using a dose conversion factor (1.40)
Start cutaquig one week after last IVIg infusion
Initial weekly does EQUALS:
Switching from another SCIg to cutaquig:
Dosing should be same as for previous SCIg
Adjust dosing according to patient’s
pharmacokinetics and clinical response
|Recommended Infusion Volume, Frequency and Rate|
|Recommended Infusion Volume||For SCIg-naïve patients, 25 mL per infusion site (maximum). If tolerated, volume can be gradually increased up to 40 mL per site.|
First 6 infusions:
|For all Sites combined |
First 6 infusions:
If tolerated, gradually increase to 50 mL, then 80 mL, up to 100 mL/hour
Please see full prescribing information for complete information on cutaquig dosing.
Dose adjustment: Over time the cutaquig dose may need to be individualized for each patient, dependent on pharmacokinetic and clinical response and on the desired IgG trough level. Measure patient’s serum IgG trough level 2 to 3 months after switching to cutaquig or after the last cutaquig dose adjustment, in order to determine if a dose adjustment is necessary.
- Calculate the difference (in mg/dL) between the patient’s target serum IgG trough level and the IgG trough level obtained during subcutaneous treatment with cutaquig. Find this difference in column 1 of the table below and locate the corresponding adjustment amount of cutaquig in mL/administration according to the body weight of the patient.
Incremental adjustment (mL) of weekly cutaquig dosing based on the calculated difference between actual IgG trough level and the target trough level for the patient.*
|Difference from Target Serum IgG Trough Level||Weight-adjusted Dose Increment (mL*)|
|30 kg||50 kg||70 kg||90 kg||110 kg|
*Derived from a linear regression model of trough levels and weekly dose per kg body weight.
- Use patient’s clinical response as primary point to consider for any dose adjustment. Additional dose increments may be indicated based on the patient’s clinical response (i.e., infection frequency and severity).
The recommended increase in weekly dose would be 37 mL.
Monitor patient’s clinical response and periodically check trough IgG levels, and repeat dose adjustment as needed.
- Cutaquig should be administered by a healthcare professional, or by caregiver or self-administered by the patient after appropriate training
- Cutaquig may be infused in the following areas: abdomen, thigh, upper arm, and/or upper leg/hip area
- Cutaquig may be infused simultaneously into up to 6 different sites. Infusion sites should be at least 2 inches (5 cm) apart. Rotate infusion sites between subsequent administrations.
Preparation and handling
The cutaquig vial is for single-use only. Discard any unused product after each infusion in accordance with local requirements.
- Cutaquig® (Immune Globulin Subcutaneous (Human) – hipp), 16.5% solution. Full Prescribing Information. Octapharma USA, December 2019.